Trium Capital’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Trium Capital’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-136,641	Closed	-$3.29M	–	101
2023 Q1	$3.29M	Buy	+136,641	New	+$1.71M	1.14%	30

Other funds holding PRVB

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Trium Capital's PRVB Position: Q2 2023 in Review

Trium Capital sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 136,641 shares — an estimated $3.29M sold.

Trium Capital first reported a position in PRVB in Q1 2023 and held it in 1 quarter. The position peaked at $3.29M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Trium Capital reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Trium Capital sold 136,641 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $3.29M.
Trium Capital first reported a position in Provention Bio, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Trium Capital's Provention Bio, Inc. Common Stock position peaked at $3.29M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Trium Capital's 13F filing for Q2 2023, filed 11 Aug 2023.